Home Featured Page 265

Featured

Latest

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine, and Scientific Rigour

After the Readout: How the Field Is Interpreting Compass’ Phase 3 Psilocybin Data

Q1’26 Psychedelic Drug Development Pipeline: Bullseye Charts

CB Therapeutics Closes on Oversubscribed Series A

Psychedelic Therapy for Borderline Personality Disorder?

Psychedelics Today’s 5th Birthday Party

Numinus Congratulates MAPS on Phase 3 Clinical Trial Demonstrating Significant Benefits...

Wesana Health Commences Trading on the CSE

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

Psychedelic Research Bulletin: April 2021

Psychedelic Bulletin: MDMA Sees Success at Phase 3; MindMed Targets Pain;...

Cancer Patients’ Life Lessons Post-Psilocybin Treatment

PTSF58 – Liberty, The Power of Therapy, and Mushrooms in Maine

EDITOR PICKS

“I’m All About the Data”: Dr. Charles Nemeroff on Psychedelics, Ibogaine,...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.